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Prior surveillance has shown that higher rates of morbidity and
mortality related to asthma occur among African-Americans
compared to other ethnic groups. OBJECTIVE: to assess uti-
lization and costs for medical services and prescription medica-
tions among African-American patients with asthma whom does
Medicaid cover. METHODS: Medical services claims with a
primary diagnosis code for asthma (ICD-9 CM 493) during cal-
endar year 2002 for recipients of African-American ethnicity
were extracted from a state Medicaid claims database. Asthma-
related prescription claims were extracted using unique and
anonymous recipient codes obtained from the medical claims.
Claims for recipients aged 65 years and older were excluded.
Cost data were from the perspective of Medicaid. RESULTS:
There were 654 African-American recipients identiﬁed with
asthma. Among these, the highest rates for asthma occurred
among males under 21 years (43 per 1000) and females over 20
years (38 per 1000). Medicaid paid over $570,000 for asthma-
related health care services for African-American recipients.
Mean costs per visit were $3409 for hospitalizations, $159 for
emergency department (ED) visits, and $102 for outpatient
visits. Compared to females, males had a higher rate of inpatient
admissions (32 per 10,000), ED visits (170 per 10,000), and out-
patient visits (68 per 1000) for asthma. Compared to children,
adults over 20 years had a higher rate of inpatient admissions
(30 per 10,000), ED visits (150 per 10,000), and outpatient visits
(68 per 1000) for asthma. The total cost for prescription med-
ications equaled approximately $256,000, at an average cost of
$49 per prescription. Of the prescription claims for asthma-
related medications, about 60% were for quick-relief medica-
tions and 40% were for maintenance drugs. Among claims for
maintenance drugs, most were for leukotriene inhibitors. CON-
CLUSIONS: Males utilized medical services more frequently
than females, as did adults compared to children. Quick-relief
medications accounted for most of the prescription claims.
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OBJECTIVES: The objective of this study was to estimate the
budget and health impact of increasing use of combination 
ﬂuticasone propionate and salmeterol (FS) in a managed care for-
mulary by adults with mild to moderate persistent asthma.
METHODS: An EXCEL-based model was developed to estimate
the impact of increasing use of FS in the mix of treatments used
for persistent asthma including ﬂuticasone proprionate (FP), sal-
meterol (SAL), other inhaled corticosteroids (ICS), leukotriene
modiﬁers (LTM), other combination therapies, and short-acting
beta-agonists (SABA). The analysis was conducted from a health
plan’s perspective. Efﬁcacy, adverse events, epidemiology, com-
pliance, and cost data were obtained from published estimates
including randomized controlled trials. The health plan was
assumed to have 1,000,000 members. Treatment mix for asthma
was based on market research data. An exponential relationship
between compliance and efﬁcacy was assumed for compliance
rates above thirty percent. RESULTS: A total of 29,050 persons
were estimated to seek treatment for persistent asthma in the
health plan. Model results comparing an FS market share of 25%
to one of 30% in the health plan show total asthma treatment
cost increases of $0.03/per member (all enrollees) per month
(PMPM) and $0.96/per asthmatic patient per month. The budget
impacts were accompanied by an annual increase of 56,555
rescue-free days and reduction of 155 exacerbations. Results are
sensitive to changes in drug costs, drugs used before FS, com-
pliance with asthma drugs, and the relationship between com-
pliance and efﬁcacy with PMPM changes ranging from a saving
of $0.01/PMPM to an increase of $0.06/PMPM for feasible alter-
native scenarios. CONCLUSION: An increase in market share
of FS will have a small impact on the overall budget of a health
plan in our base case and feasible alternative scenarios. This
budget increase will be accompanied by reductions in exacerba-
tions and other disease symptoms.
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OBJECTIVES: To determine the impact of leukotriene modiﬁers
on subsequent emergency room visits, hospitalizations and
steroid bursts; and to estimate whether leukotriene modiﬁer use
is cost-beneﬁcial. METHODS: A retrospective, longitudinal
study of 5541 adult asthmatic patients in the Ohio Medicaid
program used rate of adverse outcomes and logistic regression
to determine the impact of leukotriene modiﬁer use on three
outcome measures: emergency room visits, hospitalizations, or
steroid bursts. Propensity scores were used to control selection
bias inherent in drug treatment selection in natural databases. A
cost-beneﬁt analysis was also calculated. The cost-beneﬁt ratio
was deﬁned as the difference in asthma drug costs between the
leukotriene users and nonusers divided by the difference in
outcome costs between the users and nonusers. RESULTS:
Leukotriene modiﬁer users had 13.9 events per one hundred
patients versus the nonusers who had 11.1 events per one
hundred patients. In logistic regression models, the use of
leukotriene modiﬁers did not signiﬁcantly impact the odds of any
outcome measures: Emergency Room Visits OR 1.163, 95% CI
0.913–1.483; Hospitalizations OR 1.061, 95% CI 0.685–1.643;
Steroid Bursts OR 1.362, 95% CI 0.933–1.988. The mean cost
of all asthma drugs received by leukotriene modiﬁer users was
$327.19 and for nonusers was $186.70. The mean cost of all
outcome measures was $104.80 for leukotriene modiﬁer users
and $99.89 for nonusers. This resulted in a cost beneﬁt ratio
equal to 28.6. CONCLUSIONS: Logistic regression models
suggest that the use of leukotriene modiﬁers did not have a 
positive or negative signiﬁcant effect on any of the outcome vari-
ables. Leukotriene modiﬁer users did have higher rates of adverse
outcomes. The cost beneﬁt analysis shows that there was a total
net loss to Ohio Medicaid. The results suggest that leukotriene
modiﬁer users do not have improved outcomes or improved 
cost-beneﬁt when compared to nonusers.
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OBJECTIVE: To evaluate the resource utilization after intro-
duction of new treatment guidelines in Asthma (1997).
METHODS: Paid claims for pharmacy services during the period
1994 through 2000 were collected. Chronic users (CUs): using
more than 10 canisters of beta-inhaler/year. Patients were further
categorized: CHBYAi (CUs, using some anti-inﬂammatory 
